

BMJ Open Predicting the risk of stroke among patients with type 2 diabetes: a systematic review and meta-analysis of C-statistics

Mohammad Ziaul Islam Chowdhury,¹ Fahmida Yeasmin,² Doreen M Rabi,¹ Paul E Ronksley,³ Tanvir C Turin⁴

To cite: Chowdhury MZI, Yeasmin F, Rabi DM, *et al.* Predicting the risk of stroke among patients with type 2 diabetes: a systematic review and meta-analysis of C-statistics. *BMJ Open* 2019;**9**:e025579. doi:10.1136/bmjopen-2018-025579

► Prepublication history and additional material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2018-025579>).

Received 23 July 2018
Revised 25 July 2019
Accepted 30 July 2019



© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹Department of Community Health Sciences, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada

²Department of Mathematics and Statistics, University of Calgary, Calgary, Alberta, Canada

³Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada

⁴Department of Family Medicine, University of Calgary, Calgary, Alberta, Canada

Correspondence to

Dr Tanvir C Turin;
chowdhut@ucalgary.ca

ABSTRACT

Objective Stroke is a major cause of disability and death worldwide. People with diabetes are at a twofold to fivefold increased risk for stroke compared with people without diabetes. This study systematically reviews the literature on available stroke prediction models specifically developed or validated in patients with diabetes and assesses their predictive performance through meta-analysis.

Design Systematic review and meta-analysis.

Data sources A detailed search was performed in MEDLINE, PubMed and EMBASE (from inception to 22 April 2019) to identify studies describing stroke prediction models.

Eligibility criteria All studies that developed stroke prediction models in populations with diabetes were included.

Data extraction and synthesis Two reviewers independently identified eligible articles and extracted data. Random effects meta-analysis was used to obtain a pooled C-statistic.

Results Our search retrieved 26 202 relevant papers and finally yielded 38 stroke prediction models, of which 34 were specifically developed for patients with diabetes and 4 were developed in general populations but validated in patients with diabetes. Among the models developed in those with diabetes, 9 reported their outcome as stroke, 23 reported their outcome as composite cardiovascular disease (CVD) where stroke was a component of the outcome and 2 did not report stroke initially as their outcome but later were validated for stroke as the outcome in other studies. C-statistics varied from 0.60 to 0.92 with a median C-statistic of 0.71 (for stroke as the outcome) and 0.70 (for stroke as part of a composite CVD outcome). Seventeen models were externally validated in diabetes populations with a pooled C-statistic of 0.68.

Conclusions Overall, the performance of these diabetes-specific stroke prediction models was not satisfactory. Research is needed to identify and incorporate new risk factors into the model to improve models' predictive ability and further external validation of the existing models in diverse population to improve generalisability.

INTRODUCTION

Stroke, also known as a cerebrovascular accident, is the third leading cause of disability and accounted for over 6 million deaths

Strengths and limitations of this study

- The breadth of the comprehensive systematic literature search is a strength of this study.
- To our knowledge, this is the first study where a meta-analysis and study quality assessment was performed on stroke prediction models in patients with diabetes.
- We were only able to use C-statistics to compare the model performance, which might be insensitive to identify differences in models' ability to accurately risk-stratify patients into clinically meaningful risk groups.

worldwide in 2015.^{1 2} Diabetes mellitus, characterised by chronic hyperglycaemia due to an absolute or relative deficiency in insulin, is a major risk factor for stroke. People with diabetes are at a twofold- to fivefold increased risk for stroke compared with people without diabetes.³⁻⁷ Large clinical trials performed in people with diabetes supports the need for targeted cardiovascular risk reduction strategies to prevent the onset, recurrence and progression of acute stroke.⁸

Risk prediction models are statistical tools to estimate the probability that an individual with specific risk factors (eg, diabetes mellitus) will develop a future condition, such as stroke, within a certain time period (eg, 5 years).⁹ Such tools for the estimation of stroke risk are frequently used to assist in decisions about clinical management for both individuals and populations. Accurate risk prediction of stroke is thus necessary to provide patients with accurate information on the expected benefit from a therapy or intervention. The importance of well-performing prediction models is increasingly being recognised and health researchers continue to develop parsimonious risk prediction models under different scenarios

to meet this demand. Model performance statistics, such as C-statistic or AUC (area under the receiver operating characteristic curve) are indicators frequently used to identify models with the best predictive ability. These metrics can be compared and assessed through a formal systematic review and meta-analysis. Performing a systematic review and meta-analysis can also provide a comprehensive quantitative summary of the predictive ability of these models and evaluate their predictive performance within the available literature.

Risk factors for stroke include lifestyle-related factors,^{10 11} predisposing medical conditions,^{10 12} specific genetic diseases,^{13 14} as well as sociodemographic factors.^{11 12} Over the past decade, a number of prediction models (or risk scores) have been developed incorporating these risk factors to predict a person's risk of developing stroke.¹⁵ Prediction of stroke is important for a number of reasons: to detect or screen high-risk subjects to prevent developing stroke through early interventions, to facilitate patient–doctor communication based on more objective information and to help patients to make an informed choice regarding their treatment. While multiple stroke prediction models have been proposed in patients with diabetes, little is known about which is the most accurate one. There has also been a lack of consistency in estimating risk across these different models. With this in mind, we aimed to systematically identify all prediction models for stroke that have been applied to patients with diabetes. We characterised the study populations in which these models were derived and validated. We also assessed the predictive performance and generalisability of these stroke prediction models so that the selection of models for clinical implementation can be informed.

METHODS

Data sources and searches

Similar to previously employed methodology,¹⁶ we searched MEDLINE, EMBASE and PubMed (from database inception to 22 April 2019) for studies predicting the risk of stroke among patients with diabetes. We also searched the reference lists of all identified relevant publications. The search strategy focused on three key elements: diabetes, risk prediction with specific names of known risk scores and stroke. Only studies published in English were considered. The detailed search strategy is given in online supplemental table S1.

Study selection

Eligible articles were identified by two reviewers independently using a two-step process. First, an initial screen of titles and abstracts was performed. Abstract were retained if they reported data from an original study and reported on the development and/or validation of a stroke risk prediction model for patients with type 2 diabetes. We defined a stroke risk prediction model as one combining two or more independent variables to obtain estimates of the predicted risk for developing stroke. We

considered any clinical-based or laboratory-based definition of stroke. Selected abstracts were further screened based on a full-text review. We used broad inclusion criteria to provide an extensive systematic review of the topic. There were no restrictions on study design (eg, cohort study, case–control study), geographic region or age ranges. Studies that developed prediction models for stroke in populations with type 2 diabetes and in the general population were included; however, models that were developed in the general population but did not validate their model in a type 2 diabetes population or models developed on a type 1 diabetes population were excluded. A study was included if the outcome of the prediction model was any type of stroke or stroke that was part of a composite cardiovascular disease (CVD) outcome, but excluded if the outcome was any other cardiovascular conditions (eg, coronary heart disease (CHD), coronary artery disease (CAD), heart failure). We excluded studies that did not predict stroke. Studies on recurrent stroke or other vascular conditions (eg, patients with hypertension) were also excluded. Studies that focused only on the added predictive value of new risk factors to an existing prediction model without reporting the performance of the existing model were excluded. Studies on score-based tools, such as risk charts were also excluded. Agreement between reviewers at the full-text stage was quantified using the kappa statistic. Any disagreement between reviewers was solved through consensus.

Data extraction

Data were extracted from the finally selected studies using a standardised form by two reviewers. Information collected from each study included, outcome of the prediction model, location where the model was developed, predictors included in the model, age and gender of the study participants, number of events, duration of follow-up, modelling method used, measures of discrimination and calibration of the prediction model and the external validation of the prediction model. For the external validation studies, a different data extraction sheet was used. The collected information included specifics of the validation population, number of events, type of outcome, statistical tests and measures of discrimination, and calibration of the prediction model. Study quality was assessed using the CHARMS (Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies) Checklist.¹⁷ The following items were evaluated for each study: Was inclusion/exclusion criteria for study participants specified?; Was there non-biased selection of study participants?; Did the authors discuss or consider missing values/information?; Was there blinded assessment of the outcome?; Was duration of follow-up adequate?; Were modelling assumptions satisfied?; Was the model externally validated? and Was the potential clinical utility of the model discussed in light of study limitations?

Data analysis

The selection process for this systematic review and meta-analysis is summarised using the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram.¹⁸ Discrimination is defined as any assessment of the ability of the model to differentiate between subjects who will develop stroke from those who will not. The discrimination of a prediction model is often assessed using the concordance or C-statistic (also known as AUC). Calibration is defined as any report of the agreement between predicted probabilities and observed probabilities. Calibration is assessed using goodness-of-fit tests (eg, Hosmer-Lemeshow test), calibration slopes, tabular or graphical comparisons of predicted versus observed values within groupings of predicted risk or calibration plots. In studies that only provided a C-statistic but no measure of its variance, the SE and 95% CI of the AUC (C-statistic) was calculated using the formula:

$$SE(AUC) = \sqrt{\frac{AUC[1-AUC] + [N_1 - 1] \times \left[\frac{AUC(2-AUC) - AUC^2}{N_1 \times N_2} \right] + [N_2 - 1] \times \left[\frac{2AUC^2 / (1+AUC) - AUC^2}{N_1 \times N_2} \right]}{N_1 \times N_2}}$$

where N_1 = the number of patients with stroke and N_2 = the number of patients without stroke and the upper 95% CI = $AUC + [1.96 \times SE(AUC)]$, and lower 95% CI = $AUC - [1.96 \times SE(AUC)]$.¹⁹ The summary statistic from the individual studies was the C-statistic or AUC. We

grouped studies based on the outcome of the risk prediction models developed in diabetes populations, whether stroke was the primary outcome of the model or stroke was a part of composite CVD outcome. Random effects meta-analysis was used to obtain the pooled weighted average C-statistic with 95% CIs for common groups of models using the DerSimonian and Laird method.²⁰ Heterogeneity was assessed using the Cochran Q and the I^2 statistic and was explored using meta-regression and stratified analyses according to model outcomes. Small study effects were examined using funnel plots and Begg's test. The analyses were performed using Stata version 13.1 (Stata, College Station, Texas, USA) using the metan, metareg, metabias and metafunnel commands.

Patient and public involvement

There was no direct patient or public involvement in this review.

RESULTS

The search retrieved 21 797 citations (after duplicate removal) with an additional 63 potentially relevant papers retrieved from our grey literature search. After title and abstract screening, 262 studies were selected for full-text screening. After examining the full-text papers, 56 studies remained (reasons for exclusion stated




Figure 1 PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) diagram for systematic review of studies presenting stroke prediction models developed or validated in individuals with diabetes.

in figure 1), describing 38 models predicting stroke in patients with diabetes. Agreement between reviewers on the final articles eligible for inclusion in the systematic review was good ($\kappa=0.83$). Of these 38 models, 34 were specifically developed in patients with diabetes and 4 were developed in the general population but later externally validated in patients with diabetes. Among the models developed in patients with diabetes, nine models reported their outcome as stroke and presented a corresponding performance measure (C-statistic) for the models. Twenty-three models reported their outcome as a composite CVD outcome where stroke was one of the components and presented the model's performance measure (C-statistic) for the composite CVD outcome. Among the models developed in the general population, one model reported its outcome as stroke and three models reported a composite CVD outcome, which included stroke. Of these 38 prediction models, 17 were validated by 33 studies (some studies validated more than one model in the same study), of which 10 models had multiple validations, 7 models had a single validation and 21 models were not validated. Among the models with multiple validations, eight models were developed in a diabetes population (validated by 31 studies) and two were developed in the general population (validated by four studies). United Kingdom Prospective Diabetes Study (UKPDS) Risk Engine for Stroke by Kothari *et al*²¹ was the most validated risk score (validated by 12 studies). Figure 1, describes the systematic selection process of studies presenting a stroke prediction model applicable to patients with diabetes.

Predicting the risk of stroke within models developed in populations with diabetes

Table 1 describes the study characteristics of the nine risk prediction models developed in diabetes populations and presented a corresponding performance measure. The number of participants ranged from 1748 to 26 140 in the model development. The outcome of most models was stroke regardless of type. Duration of follow-up (total/median/mean) ranged from 501 days to 10.5 years with six models having ≥ 5 years of follow-up (defined as long duration) and three models with < 5 years of follow-up. Most of the prediction models were developed using Cox proportional hazards modelling techniques. The number of predictors included in the prediction models ranged from 4 to 29 with an average of 11 predictors per model. Several predictors were common to multiple models including age, sex, duration of diagnosed diabetes, systolic blood pressure and haemoglobin A1c (HbA1c). Only two models were externally validated after their development and four of them had never been validated in an external population. Calibration of the prediction model was reported by six studies (most commonly using the Hosmer-Lemeshow test). Discrimination was assessed using the C-statistic (or AUC) and reported by six models with values ranging from 0.64 to 0.80. The median C-statistic of the models was 0.71 with a large

amount of unexplained heterogeneity in the discriminative performance of these models ($I^2=94.6\%$; Cochran Q-statistic $p<0.001$; figure 2). Stratifying pooled results by sample size (small vs large, $p=0.19$), follow-up time (short vs long, $p=0.60$), variables included in the model (few vs many, $p=0.24$) and geographic location (Asia vs others, $p=0.60$) did not explain the observed heterogeneity in the discriminative performance of these models. The discriminative ability of the model by Kiadaliri *et al*²² was highest (C-statistic=0.80). The funnel plot and Begg's test ($p>0.999$) suggested the absence of small study effects, with no correlation between studies of smaller cohorts reporting higher C-statistics (online supplemental figure S1).

A set of nine criteria was used to assess the quality of the studies and was summarised in table 2. All the studies specified inclusion/exclusion criteria. Non-biased selection of study participants was clear in all studies except the study by Palmer *et al*.²³ Handling of missing values was reported in four (44%) studies, modelling assumptions was satisfied by two studies and model external validation was performed in two studies. Stevens *et al* was the only study to mention whether the outcome was assessed without knowledge of the candidate predictors.²⁴ Duration of follow-up was long (≥ 5 years) in six models (67%). The clinical utility of the models was discussed in six (67%) studies and almost all studies reported their study limitations.

Predicting risk of stroke (as part of a composite CVD outcome) in populations with diabetes

We identified 23 models developed in diabetes populations that reported their outcome as a composite of CVD. A summary of the characteristics of these prediction models is described in table 3. The number of participants considered in the model development ranged from 132 to 181 619 with an average age of >50 years. Duration of follow-up (mean, median, maximum) ranged from 11 months to 11.8 years with 14 models with ≥ 5 years and nine models with < 5 years of follow-up. The number of predictors included in prediction models ranged from 4 to 18 with an average of 11 predictors per model. The most common predictors included in the models were age, sex, systolic blood pressure and HbA1c, smoking and high-density lipoprotein-cholesterol. Four models were externally validated after its development and 17 of them had never been validated in an external population. Calibration of the prediction models was reported by 13 studies while discrimination reported by almost all studies with C-statistics ranging from 0.60 to 0.92. The median C-statistic of the models was 0.70 with a large amount of unexplained heterogeneity in the discriminative performance of these models ($I^2=93.7\%$; Cochran Q-statistic $p<0.001$; figure 3). Sample size (small vs large, $p=0.46$), models' external validation (externally validated vs not externally validated, $p=0.71$), variables included in the model (few vs many, $p=0.21$) and geographic location (Europe vs others, $p=0.08$) were not identified as significant sources of heterogeneity in the discriminative

Table 1 Characteristics of prediction models when outcome and corresponding performance measure (C-statistic) were reported for stroke

Study	Location	Outcome	No of Predictors	Age	Gender	Events (n)/total participants (n)	Duration of follow-up	Modelling method	Calibration	Discrimination (with CI)	External Validation
Yang <i>et al</i> ³⁸	Hong Kong, China	Stroke (stroke or deaths from stroke), haemorrhagic stroke and ischaemic stroke	4 (age, A1C, spot urine ACR and history of CHD)	Median age 57 years	Both male and female	372/7209	Median follow-up 5.37 years	Cox proportional hazard model	The Life Table Method. Adequate calibration, value NR.	Adjusted: AUROC=0.776 (considering follow-up time and censoring); unadjusted AUROC=0.749 (0.716 to 0.782)	No
Kothari <i>et al</i> ²¹	UK	Stroke (defined as a neurological deficit with symptoms or signs lasting 1 month or more)	7 (duration of diabetes, age, sex, smoking, systolic blood pressure, total cholesterol to high-density lipoprotein cholesterol ratio and presence of atrial fibrillation)	25 to 65 years	Both male and female	188/4549	Median follow-up 10.5 years	Maximum likelihood estimation using the Newton-Raphson method	NR	NR	Yes
Wells <i>et al</i> ¹⁷	USA	CHD, heart failure, stroke, mortality	29 (different variables for different models)	18 years of age or older	Both male and female	Stroke: 1088/26140	Median follow-up 501 days (Stroke model)	Competing risks regression model	Calibration plot (predicted risk against actual risk): less-well calibration (stroke and mortality)	C-statistic=0.6881 (stroke)	No
Stevens <i>et al</i> , UKPDS 66 ²⁴	UK	MI case fatality and stroke case fatality	5 (sex, HbA1c, SBP, previous stroke, white cell count for Stroke model)	Between 25 and 65 years	Both male and female	Stroke: 234/5102	Median follow-up of 7 years	Stepwise selection algorithm	HL test: p=0.248 (Stroke model)	NR	No
Tanaka <i>et al</i> /JJ Risk Engine ⁴⁹	Japan	CHD, stroke, non-cardiovascular mortality, overt nephropathy and progression of retinopathy	11 (sex, age, HbA1c, years after diagnosis, BMI, non-HDL cholesterol, ACR, atrial fibrillation, current smoker and leisure-time physical activity)	40–84 years	Both male and female	Stroke: 89/1748	Median follow-up of 7.2 years	Cox regression model	HL test: p=0.12 (Stroke model)	C-statistic=0.636 (0.564 to 0.708) (Stroke model)	No
Palmer <i>et al</i> (IRS) ²³	Scotland	Fatal or non-fatal stroke	5 genotypes (IL-6 GG/GC, MCP-1 GG, ICAM-1 EE, sel-E RR and MMP-3 5A5A)	Mean age 64.5±11.7 years	Both male and female	108/2182	Mean follow-up of 6.2±1.1 years	Cox regression model	NR	NR	No
Kiadaliri <i>et al</i> ²	Sweden	First and second events of: AMI, heart failure, non-acute ischaemic heart disease and stroke	12 (age, TC/HDL, diabetes duration, HbA1c, BMI, SBP and diastolic BP, history of events before diagnosis, LDL cholesterol, albuminuria, smoking status, BMI and gender)	Male: mean age, 55.36±9.28 years; Female: mean age, 57.15±9.55 years	Both male and female	993/21775 (first stroke); 314/21775 (second stroke)	82232 person-years for first stroke and 4127 person-years for second stroke	Weibull proportional hazard model	HL χ^2 statistic: 11.22 (p=0.19) (first stroke); 8.09 (p=0.43) (second stroke)	C-statistic=0.80 (0.78 to 0.82) (first stroke); C-statistic=0.74 (0.71 to 0.77) (second stroke)	No

Continued

Table 1 Continued

Study	Location	Outcome	No of Predictors	Age	Gender	Events (n)/total participants (n)	Duration of follow-up	Modelling method	Calibration	Discrimination (with CI)	External Validation
Li <i>et al</i> ⁴⁹	Taiwan	Ischaemic stroke	14 (age, gender, smoking habit, duration of type 2 diabetes, blood pressure, HbA1c level, total cholesterol to HDL ratio, creatinine, fasting plasma glucose variation, arterial embolism and thrombosis, diabetes, retinopathy, hypoglycaemia, antidiabetes medication use and cardiovascular medication)	30–84 years	Both male and female	2091 (derivation set), 1076 (validation set)/18 750 (derivation set), 9374 (validation set)	Mean follow-up of 8 years	Cox proportional hazard regression model	NR	AUROC=0.72 (3 years); AUROC=0.71 (5 years); AUROC=0.68 (8 years)	No
Basu <i>et al</i> /RECODE ⁴⁸	USA and Canada	Microvascular: retinopathy, neuropathy; Cardiovascular: composite of atherosclerotic cardiovascular disease (first fatal or non-fatal MI or stroke), fatal or non-fatal MI, fatal or non-fatal stroke, congestive heart failure, or death from any cardiovascular cause	14 (Age, sex, ethnicity, smoking, SBP, history of CVD, blood pressure-lowering drugs use, statin use, anticoagulants use, HbA1c, total cholesterol, HDL cholesterol, serum creatinine, urine ACR)	40–79 years	Both male and female	197 (stroke)/9635	Median follow-up of 4.7 years	Cox proportional hazard models	Calibration slope=1.16, $\chi^2=7.4$, p value=0.38 (internal validation); calibration slope=0.99, $\chi^2=8.2$, p value=0.22 (external validation)	C-statistic for stroke=0.70 (0.66 to 0.74) (internal validation); C-statistic for stroke=0.67 (0.63 to 0.71) (external validation)	Yes

ACR, albumin-to-creatinine ratio; AMI, acute myocardial infarction; AUROC, area under the receiver operating characteristic curve; BMI, body mass index; BP, blood pressure; CHD, coronary heart disease; CVD, cardiovascular disease; HDL, high-density lipoprotein; HL, Hosmer-Lemeshow; HbA1C, haemoglobin A1C; IRS, inflammatory risk score; JI, The JDCS/J-EDIT; LDL, low-density lipoprotein; MI, myocardial infarction; NR, not reported; RECODE, Risk Equations for Complications of Type 2 Diabetes; SBP, systolic blood pressure; TC, total cholesterol; UKPDS, United Kingdom Prospective Diabetes Study.




Figure 2 Forest plot of C-statistics, with 95% CIs of risk prediction models when outcome was reported for stroke.

performance of these models. The discriminative ability of the model by Ofstad *et al*²⁵ was highest (C-statistic=0.92) when novel risk markers were added to their standard model. The funnel plot and Begg’s test (p=0.24) suggested the absence of small study effects, with no correlation between studies of smaller cohorts reporting higher C-statistics (online supplemental figure S2). Only four models were developed using logistic regression models while others were developed mostly using Cox proportional hazards models.

The study quality for this group of models is summarised in table 4. Similar to the models developed in diabetic populations that look at the outcome of stroke specifically, we found that study quality was similar.

Validation studies of stroke prediction models developed in populations with and without diabetes

Seventeen risk prediction models for stroke (developed both in patients with diabetes and in general populations) were validated in diabetes populations by 33 studies (table 5). Among the 17 validated models, 14 of them were externally validated in independent cohorts and 3 of them were internally validated in a test sample or separate data set from the same cohort. Three studies validated more than one risk model in the same cohort. Models with multiple validations (two or more) and reported C-statistics are provided in figure 4. Models that had only been validated once were excluded from meta-analysis. In addition, only those studies that provided enough information to estimate the variance of the provided C-statistic for meta-analysis were considered for analysis.

UKPDS Risk Engine for Stroke by Kothari *et al*²¹ was the most frequently externally validated model with a total of 12 studies reporting its performance in different diabetes cohorts. In 12 external validation studies, a total of 126 323 patients were included with considerable variations in sample sizes across the different studies. The pooled C-statistic for the model by Kothari *et al*²¹ was 0.72

Table 2 Study quality assessment of prediction models when outcome and corresponding performance measure (C-statistic) were reported for stroke

Study	Inclusion/exclusion criteria specified	Non-biased selection	Missing value/loss to follow-up considered	Modelling assumptions satisfied	Model external validation	Outcome assessed without knowledge of the candidate predictors (ie, blinded)	Duration of follow-up long enough	Potential clinical use of the model discussed	Study limitations discussed
Yang <i>et al</i> ³⁵	Yes	Yes	Not clear	No	No	Not clear	Yes	Yes	Yes
Kothari <i>et al</i> ²¹	Yes	Yes	No	Yes	Yes	Not clear	Yes	Yes	Yes
Wells <i>et al</i> ⁴⁷	Yes	Yes	Yes	No	No	Not clear	No	Yes	Yes
Stevens <i>et al</i> (UKPDS 66) ²⁴	Yes	Yes	Not clear	No	No	Yes	Yes	Yes	No
Tanaka <i>et al</i> (JJ Risk Engine) ³⁶	Yes	Yes	Yes	No	No	Not clear	Yes	No	Yes
Palmer <i>et al</i> (IRS) ²³	Yes	Not clear	No	No	No	Not clear	Yes	No	Yes
Kiadaliri <i>et al</i> ²²	Yes	Yes	Yes	No	No	Not clear	No	No	Yes
Li <i>et al</i> ⁴⁹	Yes	Yes	Yes	Yes	No	Not clear	Yes	Yes	Yes
Basu <i>et al</i> (RECODE) ³⁶	Yes	Yes	No	Not clear	Yes	Not clear	No	Yes	Yes

IRS, inflammatory risk score; JJ, The JDCS/J-EDIT; RECODE, Risk Equations for Complications of Type 2 Diabetes; UKPDS, United Kingdom Prospective Diabetes Study.

Table 3 Characteristics of prediction models when stroke is reported as a part of composite CV outcome and performance measure (C-statistic) is presented for the composite CV outcome

Study	Location	Outcome	No of predictors	Age	Gender	Events (n)/total participants (N)	Duration of follow-up	Modelling Method	Calibration	Discrimination (with CI)	External Validation
Brownrigg <i>et al</i> ⁵	England	CVD events (non-fatal MI, coronary revascularisation, congestive cardiac failure, transient ischaemic attack and stroke)	6 (age, sBP, smoking status, LDL-C and HDL-C and peripheral neuropathy)	Mean age of 63.8 years	Both male and female	399/13 043	Total 2.5 years	Probability weighted Cox regression	$\chi^2=121.2$, $p<0.001$	C-statistic=0.661 (0.636 to 0.686) (with PN)	No
Khalili <i>et al</i> ⁶⁰	Iran	CVD events (definite MI, probable MI, unstable angina, angiographic-proven CHD, stroke, death from CVD)	4 (BMI, waist circumference, WHR, and waist-to-height ratio)	Mean age 55.7 years (male), 52.7 years (female)	Both male and female	188/1010	Median follow-up 8.4 years	Cox proportional hazard model	NR	C-statistic=0.64 (0.58 to 0.70) (for diabetic men with WHR, model 2) and C-statistic=0.70 (0.65 to 0.75) (for diabetic women with WHR, model 2)	No
Cederholm <i>et al</i> ⁶¹	Sweden	Fatal or non-fatal CVD (CHD or stroke, whichever came first)	9 (A1C, age at the onset of diabetes, diabetes duration, sex, BMI, smoking, sBP, antihypertensive drugs and lipid-reducing drugs)	18–70 years	Both male and female	1482/11 646	Mean follow-up 5.64 years	Cox regression	HL test: $\chi^2=4.29$ ($p=0.83$) and the ratio of observed to predicted survival rates=0.999. Excellent calibration	C-statistic=0.70	No
Davis <i>et al</i> ⁶³	Australia	CVD (hospitalisation for/with MI or stroke, and death from cardiac or cerebrovascular causes or sudden death)	7 (age, sex, prior CVD, ln (urinary albumin : creatinine ratio), lnHbA1c, ln(HDL-C), Southern European ethnic background and aboriginality)	Mean age 64.1 (58.7–83.7) years	Both male and female	185/1240	Mean follow-up 4.5 years	Cox proportional hazards model	HL-C test, $p=0.74$	AUC=0.80, $p<0.001$	Yes
Kengne <i>et al</i> ⁶⁴	20 Countries (Asia, Australasia, Europe and Canada)	CVD (fatal or non-fatal MI or stroke or CV death)	10 (age at diagnosis, known duration of diabetes, sex, pulse pressure, treated hypertension, atrial fibrillation, retinopathy, HbA1c, log of urinary albumin/creatinine ratio and non-HDL-C at baseline)	Mean age 65.8 (6.3) years	Both male and female	473/7168	4.5 years	Cox regression model	HL test: $p=0.76$ (ADVANCE cohort)	AUC=0.702 (0.676 to 0.728) (ADVANCE cohort)	Yes
Ofstad <i>et al</i> ⁶⁵	Norway	Death or first CV event (MI, stroke or hospitalisation for unstable angina pectoris)	11 (age, gender, known CVD, dB, microalbuminuria, serum levels of HDL-C and creatinine); novel risk markers: (IL-6, log Activin A, E/Em, pathol recovery/loop)	Mean age 58.5±10.0 (SD) years	Both male and female	36/132	8.6±2.1 years	Cox proportional hazard model	NR	C-statistic: STD model: 0.794; STD + IL-6 model: 0.913; STD + log Activin A model: 0.859; STD + IL-6 + log Activin A model: 0.923; STD + E/Em + pathol recovery/loop model: 0.891	No
Looker <i>et al</i> ⁶²	Five cohorts from Europe	CVD (acute CHD or an ischaemic stroke)	14 (age, sex, smoking, sBP and dBp, LDL-C, HDL-C, triacylglycerol, diabetes duration, HbA1C, BMI, height, (eGFR), cohort and current medication (including antihypertensive agents, aspirin, lipid-lowering agents and insulin therapy)). +6 Biomarkers (NT-proBNP +6 Biomarkers (NT-proBNP apoCIII hsTnT IL-6 sPAGE IL-15)	Median age 68.4 years (controls) and 68.8 years (cases)	Both male and female	1123/2310	Median follow-up 3.2 years for cases and 6.5 years for controls	Forward selection using logistic regression	NR	AUROC=0.72 (full clinical covariate set plus forward selection biomarkers)	No

Continued

Table 3 Continued

Study	Location	Outcome	No of predictors	Age	Gender	Events (n)/total participants (N)	Duration of follow-up	Modelling Method	Calibration	Discrimination (with CI)	External Validation
Mukamal <i>et al</i> ³²	USA	MI, stroke, CV death	7 in basic model (Age, smoking, SBP, total and HDL-C, creatinine and the use of glucose-lowering agents)	Mean age 72.6 years for female and 73.0 years for male	Both male and female	265/782	10 years	Cox proportional hazard model	Basic model: HL p=0.25; basic model+CRP: HL p=0.87; Basic Model+CRP + (ABI, internal carotid wall thickness, ECG left ventricular hypertrophy): HL p=0.65	Basic model: C-statistic=0.64; Basic model+CRP: C-statistic=0.64; Basic model+CRP + (ABI, internal carotid wall thickness, ECG left ventricular hypertrophy): C-statistic=0.68	Yes
Paynter <i>et al</i> ³³	USA	MI, ischaemic stroke, coronary revascularisation or CV death	8 in different models (age, SBP, total cholesterol, HDL-C, smoking, CRP, parental history of premature MI and HbA1c)	Median age 55 years for female and 67.8 years for male	Both male and female	125/685 (women); 170/563 (men)	Median follow-up 10.2 years (women); median follow-up 11.8 years (men)	Cox proportional hazards model	NR	C-statistic of model with HbA1c=0.692 (ATP II) and=0.697 (RRS) for women; C-statistic of model with HbA1c=0.602 (ATP II) and=0.605 (RRS) for men.	No
Price <i>et al</i> ³⁴	Scotland	All CV events (fatal and non-fatal MI, angina, fatal IHD, fatal and non-fatal stroke and TIA)	18 (age, sex, baseline CVD status, duration, diabetes treatment, lipid-lowering drugs, BP-lowering drugs, smoking status, BMI, SBP, dBP, HbA1c, HDL-C, total cholesterol, eGFR, microalbuminuria and social status +NT-proBNP) (model D)	60–75 years	Both male and female	112/1066	4 years	Cox proportional hazards model	NR	C-statistic=0.748 (0.691 to 0.805) (model D)	No
Selby <i>et al</i> ³⁵	USA	Macrovascular and microvascular complications (MI, other ischaemic heart disease, congestive heart failure, cerebrovascular accident, etc)	16 (outpatient diagnoses, inpatient events, age, antihypertensives, serum creatinine, diabetes treatment, mean HbA1c, albuminuria, primary care visits, outpatient diagnoses of obesity, outpatient ID diagnoses, mean total cholesterol, self-report of neuropathy, education, type of diabetes, sex)	Mean age of 60.8 years	Both male and female	1997/28 838	1 year	Logistic regression model	NR	AUC=0.64 (full model)	No
Zethelius <i>et al</i> ³⁵	Sweden	Fatal/non-fatal CVD (the composite of CHD or stroke)	12 (onset age of diabetes, diabetes duration, total-cholesterol-to-HDL-C ratio, HbA1c, SBP, BMI, males sex, smoker, microalbuminuria, macroalbuminuria, atrial fibrillation, previous CVD)	30–74 years	Both male and female	2488/24 288	Mean follow-up of 4.8 years	Cox proportional hazard model	Modified HL χ^2 statistic=0.13 (p=0.9)	C-statistic=0.71	No
Alrawahi <i>et al</i> ³¹	Oman	First fatal or non-fatal CHD, stroke, or PAD	7 (age, diabetes duration, HbA1c, total cholesterol, albuminuria, hypertension, BMI)	54.5±11.4 years	Both male and female	192/2039	Mean follow-up of 5.3 years	Cox regression model	NR	NR	No

Continued

Table 3 Continued

Study	Location	Outcome	No of predictors	Age	Gender	Events (n)/total participants (N)	Duration of follow-up	Modelling Method	Calibration	Discrimination (with CI)	External Validation
Zarkogianni <i>et al</i> ⁶⁶	Greece	Fatal or non-fatal CVD: stroke and CHD	16 (age, diabetes duration, BMI, glycosylated haemoglobin, pulse pressure, fasting glucose, total cholesterol, triglycerides, HDL-C, smoking habit, sex, hypertension, lipid-lowering therapy, aspirin, insulin therapy, parental history of diabetes)	58.56±10.70 years	Both male and female	41/560	5-year follow-up	Machine learning: HWNNs and SOMs	Brier score: 0.08±0.01 (HWNN-based ensemble 4); 0.07±0.01 (SOM-based ensemble 4); 0.007±0.02 (hybrid ensemble)	AUC=0.6764±0.1509 (HWNN-based ensemble 4); AUC=0.7054±0.1372 (SOM-based ensemble 4); AUC=0.7148±0.1573 (hybrid ensemble)	No
Price <i>et al</i> ⁶⁷	Scotland	Fatal or non-fatal MI or stroke, angina, fatal IHD, TIA, coronary intervention	13 (age, sex, smoking, atrial fibrillation, CKD, arthritis, hypertension, BMI, SBP, total HDL-C, social status, baseline CVD status, lipid-lowering medication) in basic model + (ABI, hs-cTnT, GGT, proBNP, g) in full model	60–75 years	Both male and female	205/1066	8 years	Binary logistic regression	HL p=0.97 (basic model); HL p=0.39 (full model). Well calibrated	C-statistic=0.722 (0.681 to 0.763) (basic model); C-statistic=0.74 (0.699 to 0.781) (full model)	No
Wan <i>et al</i> ⁶⁸	China	IHD, MI, coronary death and sudden death, heart failure, fatal and non-fatal stroke	13 (age, eGFR, total cholesterol/HDL-C ratio, urine ACR, smoker, duration of diabetes mellitus, SBP, HbA1c, anti-hypertensive drugs used, dBP, BMI, insulin used, anti-glucose oral drugs used)	18–79 years	Both male and female	Events (n) NR/137 935	Median follow-up of 5 years	Cox proportional hazard regression	Calibration plots: good calibration	Harrell's C-statistic Male: 0.705 (0.693 to 0.716) (model 1), 0.689 (0.678 to 0.701) (model 2); Female: 0.719 (0.707 to 0.731) (model 1), 0.708 (0.696 to 0.719) (model 2)	No
Young <i>et al</i> ⁶⁹	USA	MACE: non-fatal MI, non-fatal stroke and CVD-related death; MACE-plus: any MACE, hospitalisation for unstable angina, or hospitalisation for congestive heart failure; CVD-related death	12 (age, gender, type of insurance, race, region, diabetes-related hospitalisations, prior CVD diagnoses, chronic pulmonary disease, use of antihypertensive drugs, use of antihyperglycaemic drugs, HbA1c, urine ACR)	50 years or older	Both male and female	13 856 (MACE), 20 100 (MACE-plus)/181 619	Median duration of the at-risk period: 12 months (primary prevention population) and 11 months (secondary prevention population)	Logistic regression	NR	C-statistic=0.70 (MACE); C-statistic=0.72 (MACE-plus); C-statistic=0.77 (CVD-related death)	No
van der Leeuw <i>et al</i> ⁶⁰	The Netherlands	Major CV events (MI, stroke and vascular death)	12 (age at diabetes diagnosis, duration of diagnosed diabetes, sex, smoking, HbA1c, sBP, total cholesterol/HDL-C ratio, previous CV event, urinary ACR or eGFR) in base model+NT-proBNP, osteopontin, and MMP-3 in multimarker model	Mean age 59±10 years (SMART), 58±7 (EPIC-NL)	Both male and female	248 (SMART), 134 (EPIC-NL)/1002 (SMART), 218 (EPIC-NL)	Median follow-up 9.2 years in SMART and 11.3 years in EPIC-NL	Cox proportional hazard model	Calibration plots	Base model: C-statistic=0.70 (0.67 to 0.74) (SMART), C-statistic=0.69 (0.64 to 0.74) (EPIC-NL); Multimarker model: C-statistic=0.73 (0.68 to 0.79) (SMART), C-statistic=0.72 (0.64 to 0.77) (EPIC-NL)	No

Continued

Table 3 Continued

Study	Location	Outcome	No of predictors	Age	Gender	Events (n)/total participants (N)	Duration of follow-up	Modelling Method	Calibration	Discrimination (with CI)	External Validation
Alshehry <i>et al</i> ³¹	20 countries from Asia, Australasia, Europe and North America	Non-fatal MI, non-fatal stroke, and CV death	14 (age, sex, BMI, SBP, glycohaemoglobin, HDL-C, eGFR, diabetes duration, CRP history of macrovascular disease, history of heart failure, use of antihypertensive medication, use of antiplatelet medication, exercise) in base model + 7 lipid species	Mean age 67 years	Both male and female	698/3779	Median follow-up of 5 years	Weighted Cox regression	NR	Base model: C-statistic=0.68 (0.678 to 0.682); base model + 7 lipid species: C-statistic=0.70 (0.698 to 0.702)	No
Woodward <i>et al</i> / <i>The AD-ON Risk Score</i> ³²	20 countries from Asia, Australasia, Europe and North America	Non-fatal MI, non-fatal stroke or death from any CV cause, renal death or requirement for renal replacement therapy or renal transplantation	13 (age, sex, SBP with and without use of antihypertensives, duration of diabetes, HbA1c, urinary ACR, eGFR and its square, age at completion of formal education, exercise, history of diabetic retinopathy and current or previous atrial fibrillation)	Mean age of 65.8 years	Both male and female	1145/7301	Median follow-up of 9.9 years	Cox regression model	Calibration plots and HL test (p=0.13). Excellent calibration	C-statistic=0.668 (0.651 to 0.685)	No
Parrinello <i>et al</i> ³³	USA	Incident CHD, stroke, heart failure, CKD, lower extremity amputation or peripheral vascular bypass	18 (age, sex, race, education, smoking status, alcohol consumption, physical activity, family history of CVD, glucose-lowering medication use, antihypertensive medication use, cholesterol-lowering medication use, recent onset of diabetes, BMI, LDL-C, HDL-C, triglycerides, SBP, HbA1c) + 12 biomarkers	Mean age of 58.1 years	Both male and female	141 (CVD events)/654	Maximum follow-up of 10 years	Fine and Gray model	Calibration plots: well calibrated	C-statistic=0.667 (0.64 to 0.70) (model 1); C-statistic=0.683 (0.65 to 0.71) (model 2); C-statistic=0.694 (0.66 to 0.72) (model 3); C-statistic=0.716 (0.69 to 0.74) (model 4)	No
Colombo <i>et al</i> ³⁴	UK and Ireland	Acute CHD (MI, unstable angina, revascularisation or acute CHD death), fatal or non-fatal stroke	8 (age, sex, SBP, total cholesterol, HDL-C, smoking status, apoCIII and NT-proBNP)	Median age of 62.9 years	Both male and female	144/2105	Maximum follow-up of 5 years	Cox proportional hazard model	NR	AUROC=0.661 (0.615 to 0.706) (Framingham covariates alone); AUROC=0.745 (0.701 to 0.789) (full model with additional biomarkers)	No
Elley <i>et al</i> NZ DCS ⁴⁰	New Zealand	Fatal or non-fatal CVD event (ischaemic heart disease, cerebrovascular accident/transient ischaemic attack, PAD)	9 (age at diagnosis, diabetes duration, sex, SBP, smoking status, total cholesterol: HDL ratio, ethnicity, glycated HbA1C), urine ACR)	Median age of 59 years	Both male and female	6479/36 127	Median follow-up of 3.9 years	Cox proportional hazards regression models	Calibration plot (CVD)	AUROC=0.68 (0.67 to 0.70)	Yes

ABI, ankle-brachial index; AD-ON, Action in Diabetes and Vascular Disease: Preterax and Diamicon Modified Release Controlled Evaluation; apoCIII, Apolipoprotein C-III; ATP, Adult Treatment Panel; AUC, area under the curve; AUROC, area under the receiver operating characteristic curve; BMI, body mass index; CHD, coronary heart disease; CKD, chronic kidney disease; CRP, C reactive protein; CV, cardiovascular; CVD, cardiovascular disease; dBp, diastolic blood pressure; eGFR, estimated glomerular filtration rate; EPIC-NL, European Prospective Investigation into Cancer and Nutrition Netherlands; GGT, gamma-glutamyl transferase; HbA1c, haemoglobin A1c; HDL, high-density lipoprotein; HDL-C, high-density lipoprotein cholesterol; HL, Hosmer-Lemeshow; HL-C, Hosmer-Lemeshow C-test; cTnT, high-sensitivity cardiac troponin T; HWMNs, hybrid wavelet neural networks; ID, infectious disease; IHD, ischaemic heart disease; IL-6, interleukin 6; LDL-C, low-density lipoprotein cholesterol; MAOE, major adverse cardiovascular event; MI, myocardial infarction; MMP-3, matrix metalloproteinase-3; NR, not reported; NT-proBNP, N-terminal pro b-type Natriuretic Peptide; NZ DCS, New Zealand Diabetes Cohort Study; PAD, peripheral artery disease; PN, peripheral neuropathy; RRS, Reynolds risk score; SBP, systolic blood pressure; SMART, second manifestations of arterial disease; SOMIS, self-organising maps; STD, standard; TIA, transient ischaemic attack; WHR, waist-to-hip ratio.

C-statistics for stroke prediction models for diabetes patients

(Stroke is a part of composite cardiovascular disease outcome)




Figure 3 Forest plot of C-statistics, with 95% CIs of risk prediction models when stroke was reported as part of a composite cardiovascular disease outcome. AD-ON, Action in Diabetes and Vascular Disease:Preterax and Diamicon Modified Release Controlled Evaluation-Observational; EPIC-NL, European Prospective Investigation into Cancer and Nutrition-Netherlands; HWNNs, hybrid wavelet neural networks; MACE, major adverse cardiovascular event; NZDCS, New Zealand Diabetes Cohort Study; SMART, second manifestations of arterial disease; SOMs, self-organising maps.

(95% CI, 0.68 to 0.75), with high heterogeneity identified ($I^2=95\%$; Cochran Q statistic $p<0.001$). Stratification by sample size (small vs large, $p=0.69$), geographic location (Asia vs others, $p=0.09$) and stroke type (fatal vs non-fatal, $p=0.07$) did not explain the observed heterogeneity in the discriminative performance of this model. UKPDS Risk Engine by Stevens *et al.*²⁶ was the second most externally validated model with five validation studies including 2826 patients. One study did not report the number of participants and none of the studies reported C-statistics. As a result, a pooled C-statistic and heterogeneity was not possible to assess for this model. The UKPDS Outcomes Model by Clarke *et al.*²⁷ was externally validated by four studies including 65 056 patients. The pooled C-statistic was 0.66 (95% CI, 0.61 to 0.71) with high heterogeneity between studies ($I^2=84.5\%$; Cochran Q statistic $p=0.002$). Similar to the UKPDS Risk Engine for Stroke,²¹ stratification across select study characteristics did not explain the observed heterogeneity. The Framingham risk score by Anderson *et al.*²⁸ was externally validated in two studies including 8574 patients. The pooled C-statistic was 0.58 (95% CI, 0.54 to 0.61) with non-significant heterogeneity between studies ($I^2=56.1\%$; Cochran Q statistic $p=0.102$). The Framingham risk score by D'Agostino *et al.*²⁹ was externally validated in two studies including 7604 patients. One study (Ataoglu *et al.*³⁰) did not report the C-statistic

for the model and one study (Kengne *et al.*³¹) reported two C-statistic values, one for major events and one for any event. The pooled C-statistic for these two values was 0.58 (95% CI, 0.55 to 0.60). Models by Mukamal *et al.*,³² Davis *et al.*,³³ Kengne *et al.*³⁴ and Zethelius *et al.*³⁵ each were externally validated by two studies with pooled C-statistics of 0.67 (95% CI, 0.67 to 0.68), 0.75 (95% CI, 0.58 to 0.92), 0.67 (95% CI, 0.65 to 0.69) and 0.69 (95% CI, 0.63 to 0.75), respectively. Observed heterogeneity was high in models by Davis *et al.*³³ and Zethelius *et al.*³⁵ while low in models by Mukamal *et al.*³² and Kengne *et al.*³⁴ The model by Basu *et al.*³⁶ was externally validated by two studies in three different population yielding a pooled C-statistic of 0.71 (95% CI, 0.67 to 0.76) with moderate heterogeneity between studies ($I^2=56.8\%$; Cochran Q statistic $p=0.099$).

Separate models by D'Agostino *et al.* (Framingham Stroke Risk Score),³⁷ Yang *et al.* (Hong Kong Diabetes Registry for Stroke),³⁸ Kiadaliri *et al.*,²² Stevens *et al.* (UKPDS 66),²⁴ Hippisley-Cox *et al.* (QRISK2),³⁹ Elley *et al.* (New Zealand Diabetes Cohort Study)⁴⁰ and Alrawahi *et al.*⁴¹ were each validated in one external or separate cohort with sample sizes ranging from 178 to 181 399 patients. For the studies that reported discrimination, C-statistics ranged from 0.67 to 0.79. In addition, calibration assessed by calibration plots and Hosmer-Lemeshow tests found good calibration in most studies.

Table 4 Study quality assessment of prediction models when stroke is reported as a part of composite CV outcome and performance measure (C-statistic) is presented for the composite CV outcome

Study	Inclusion/ exclusion criteria specified	Non-biased selection	Missing value/ loss to follow-up considered	Modelling assumptions satisfied	Model external validation	Outcome assessed		Duration of follow-up long enough	Potential clinical use of the model discussed	Study limitations discussed
						without knowledge of the candidate predictors (ie, blinded)	of the model discussed			
Brownrigg <i>et al.</i> ¹⁵	Yes	No	No	No	No	Not clear	No	Yes	Yes	Yes
Khalili <i>et al.</i> ⁵⁰	Yes	No	No	Yes	No	Not clear	Yes	Yes	Yes	Yes
Cederholm <i>et al.</i> ⁵¹	Yes	Not clear	No	Yes	No	Not clear	Yes	Yes	Yes	Yes
Davis <i>et al.</i> ³³	Not clear	Not clear	No	Yes	Yes	Not clear	No	No	No	No
Kengne <i>et al.</i> ³⁴	Yes	Yes	Not clear	Not clear	Yes	Not clear	No	Yes	Yes	Yes
Ofstad <i>et al.</i> ²⁵	Yes	Not clear	Yes	Yes	No	Not clear	Yes	Yes	Yes	Yes
Looker <i>et al.</i> ⁵²	Yes	Not clear	Yes	Not Clear	No	Not clear	No	Yes	Yes	Yes
Mukamal <i>et al.</i> ⁵²	Yes	Yes	Yes	Yes	Yes	Not Clear	Yes	Yes	Yes	Yes
Paynter <i>et al.</i> ⁵³	Yes	Yes	No	No	No	Not Clear	Yes	No	No	No
Price <i>et al.</i> ⁵⁴	Yes	Not clear	Not clear	No	No	Not clear	No	No	No	Yes
Selby <i>et al.</i> ⁵⁵	Yes	Yes	Yes	No	No	Not clear	No	Yes	Yes	Yes
Zethelius <i>et al.</i> ⁵⁵	Yes	Not clear	No	Yes	No	Not clear	No	Yes	Yes	Yes
Alrawahi <i>et al.</i> ⁴¹	Yes	Yes	No	Yes	No	Not clear	Yes	Yes	Yes	Yes
Zarkogianni <i>et al.</i> ⁵⁶	No	Not clear	Not clear	Yes	No	Not clear	Yes	Yes	Yes	Yes
Price <i>et al.</i> ⁵⁷	Not clear	Yes	No	Not clear	No	Not clear	Yes	Yes	Yes	Yes
Wan <i>et al.</i> ⁵⁸	Yes	Yes	Yes	Yes	No	Not clear	Yes	Yes	Yes	Yes
Young <i>et al.</i> ⁵⁹	Yes	Yes	Not clear	Not clear	No	Not clear	Not clear	Yes	Yes	Yes
van der Leeuw <i>et al.</i> ⁶⁰	Yes	Not clear	Yes	Not clear	No	Not clear	Yes	Yes	Yes	Yes
Alshehry <i>et al.</i> ⁶¹	Yes	Yes	Not clear	Not clear	No	Not clear	Yes	Yes	Yes	Yes
Woodward <i>et al.</i> The AD-ON Risk Score ⁶²	Yes	Yes	Not clear	Not clear	No	Not clear	Yes	Yes	Yes	Yes
Parrinello <i>et al.</i> ⁶³	Yes	Yes	No	Not clear	No	Not clear	Yes	Yes	Yes	Yes
Colombo <i>et al.</i> ⁶⁴	Yes	Yes	Yes	Not clear	No	Not clear	No	Yes	Yes	Yes
Elley <i>et al.</i> NZ DCS ⁴⁰	Yes	Not clear	Yes	Yes	Yes	Not clear	No	Yes	Yes	No

AD-ON, Action in Diabetes and Vascular Disease; Preterax and Diamicron Modified Release Controlled Evaluation-Observational; NZ DCS, New Zealand Diabetes Cohort Study.

Table 5 Characteristics of the validation studies of the stroke prediction models

Study name	No of Studies	Validation study	Location	Outcome	Age	Gender	Events (n) /total participants (N)	Calibration	Discrimination (with CI)
Kothari <i>et al</i> , UKPDS Risk Engine for Stroke (UKPDS 60) ²¹	12	Kengne <i>et al</i> ³¹	20 Countries (Australasia, Asia, Europe, North America)	Major CHD, major CVD and major cerebrovascular event (death from cerebrovascular disease and non-fatal stroke)	Mean age 66 years for both males and females	Both male and female	288/7502	HL $\chi^2=138.7$ (p<0.0001) (major event); HL $\chi^2=114.3$ (p<0.0001) (any event)	AUC=0.62 (major event); AUC=0.61 (any event)
		Davis <i>et al</i> ⁶⁵	Australia	Fatal stroke, all stroke	Mean age of 62.2 years	Both male and female	13 (fatal stroke), 23 (all stroke)/791	HL χ^2 -test: p=0.06 (fatal stroke) and p=0.33 (all stroke), good calibration	AUC=0.88 (0.81 to 0.96) (fatal stroke); AUC=0.86 (0.78 to 0.93) (all stroke)
		Kothari <i>et al</i> ²¹	UK	Fatal stroke	Mean age 51.5 years for males and 52.6 years for females.	Both male and female	197/1370	NR	NR
		Jiao <i>et al</i> ⁶⁶	Hong Kong	Stroke	Mean age 64.3 years (RAMP-DM) and 65.3 years (control)	Both male and female	Total CVD events n=10 (RAMP-DM) and n=13 (control group) / RAMP-DM group n=1072, control group n=1072	NR	NR
		Yang <i>et al</i> ⁶⁸	Hong Kong, China	Stroke	Median age 57 years	Both male and female	182/3541	NR	Unadjusted AUROC=0.588 (0.549 to 0.626)
		Lahoz-Rallo <i>et al</i> ⁶⁷	Spain	Cerebrovascular risk (stroke)	Mean age 65.5 years	Both male and female	Events (n) NR / n=1846	NR	NR
		Metcalf <i>et al</i> ⁶⁸	New Zealand	Stroke	35 to 74 years	Both male and female	Events (n) NR / n=423	NR	NR
		Tanaka <i>et al</i> ⁶⁸	Japan	Stroke	40 to 84 years	Both male and female	89/1748	HL test: (p=0.54)	C-statistic=0.638 (0.566 to 0.711)
		Wells <i>et al</i> ⁴⁷	USA	Stroke	18 years of age or older	Both male and female	Events (n); stroke (1088)/total participants (N); stroke (26 140)	Risk underestimated when examining calibration in the large	C-statistic=0.752
		Bannister <i>et al</i> ⁶⁹	UK	CHD, fatal CHD, stroke, fatal stroke	Mean age 60.3 years (male) and 62.6 years (female)	Both male and female	671/779 966 (stroke), 7037/79 966 (fatal stroke)	NR	C-statistic=0.73 (0.72 to 0.75) (stroke, female), C-statistic=0.71 (0.70 to 0.72) (Stroke, male); C-statistic=0.77 (0.74 to 0.80) (fatal stroke, female), C-statistic=0.78 (0.76 to 0.81) (fatal stroke, male)

Continued

Table 5 Continued

Study name	No of Studies	Validation study	Location	Outcome	Age	Gender	Events (n) /total participants (N)	Calibration	Discrimination (with CI)
		Wu <i>et al</i> ⁷⁰	China	Stroke and CHD	20 years and above	Both male and female	Events (n) NR/ n=1584	NR	NR
		Ipadeola <i>et al</i> ⁷¹	Nigeria	CHD and stroke	Mean age 60.5±9.89 years	Both male and female	Events (n) NR/340	NR	NR
Clarke <i>et al</i> , UKPDS Outcomes Model ²⁷	4	Leal <i>et al</i> ⁷²	UK	MI/stroke/IHD/heart failure/amputation/blindness/renal failure/death from any cause	Mean age 62 years	Both male and female	Events (n) NR/ n=4031	Calibration plots: overestimated	C-statistic=0.68 (0.65 to 0.71) (stroke)
		McEwan <i>et al</i> ⁷³	UK	CHF/IHD/MI/stroke/blindness/ESRD/amputation	Mean age 51.49 years (low risk) and 66.08 years (intermediate)	Both male and female	723 (stroke)/54 169 (all in low-risk patient)	NR	ROC=0.62 (stroke)
		Pagano <i>et al</i> ⁷⁴	Italy	MI, other IHD, stroke, CHF and amputation (2000 survey) and mortality (1991 survey)	Mean age 57.9 years (1991 survey) and 57.4 years (2000 survey)	Both male and female	Events (n) NR/ n=2514 (2000 survey) and n=1443 (1991 survey)	NR	NR
		Tao <i>et al</i> ⁷⁵	UK, Denmark and the Netherlands	MI and stroke	40–69 years (50–69 years in the Netherlands)	Both male and female	Events (n) NR/2899	HL test: p=0.33 (Stroke)	AUROC=0.70 (0.64 to 0.77) (stroke)
Stevens <i>et al</i> , UKPDS Risk Engine (UKPDS 56) ²⁶	5	Shivakumar <i>et al</i> ⁷⁶	India	CHD and stroke	Mean age 63.3 years	Both male and female	NR	NR	NR
		Moazzam <i>et al</i> ⁷⁷	Pakistan	CHD, fatal CHD, stroke, fatal stroke	30–74 years	Both male and female	Events (n) NR/470	NR	NR
		Ezenwaka <i>et al</i> ⁷⁸	Trinidad and Tobago	Absolute CHD and stroke	Mean age 63.1 years (male) and 59.5 years (female)	Both male and female	Events (n) NR/325	NR	NR
		Sun <i>et al</i> ⁷⁹	China	CHD and stroke	21–94 years (58.4±12.9 years)	Both male and female	Events (n) NR/853 (no. of patients with CKD)	NR	NR
		Pang <i>et al</i> ⁸⁰	China	CHD and stroke	21–90 years	Both male and female	Events (n) NR/1178	NR	NR

Continued

Table 5 Continued

Study name	No of Studies	Validation study	Location	Outcome	Age	Gender	Events (n) /total participants (N)	Calibration	Discrimination (with CI)
Anderson <i>et al.</i> , (Framingham Risk Score) ²⁹	2	Herder <i>et al.</i> ⁸¹	Germany	MI, stroke, cardiovascular death	NR	Both male and female	84/1072	Observed/expected events reported. Good calibration (p>0.05) in all quintiles except quintile 4	C-statistic=0.636
D'Agostino <i>et al.</i> , (Framingham Risk Score) ²⁹	2	Kengne <i>et al.</i> ³¹	20 countries (Australasia, Asia, Europe, North America)	Major CHD, major CVD and major cerebrovascular event (death from cerebrovascular disease and non-fatal stroke)	Mean age 66 years for both male and female	Both male and female	288/7502	HL $\chi^2=42.7$ (p<0.0001) (major event); HL $\chi^2=149.0$ (p<0.0001) (any event)	AUC=0.568 (major event); AUC=0.555 (any event)
D'Agostino <i>et al.</i> , (Framingham Risk Score) ²⁹	2	Ataoglu <i>et al.</i> ³⁰	Turkey	Cardiovascular death, non-fatal MI, angina, ischaemic stroke	NR	Both male and female	66/102	NR	NR
D'Agostino <i>et al.</i> , (Framingham Stroke Risk) ³⁷	1	Kengne <i>et al.</i> ³¹	20 countries (Australasia, Asia, Europe, North America)	Major CHD, major CVD and major cerebrovascular event (death from cerebrovascular disease and non-fatal stroke)	Mean age 66 years for both male and female	Both male and female	288/7502	HL $\chi^2=19.9$ (p=0.0004) (major event); HL $\chi^2=32.7$ (p<0.0001) (any event)	AUC=0.587 (major event); AUC=0.567 (any event)
Yang <i>et al.</i> , (Hong Kong Diabetes Registry for Stroke) ³⁸	1	Costa <i>et al.</i> ⁸²	Spain	Stroke	55-85 years	Both male and female	9/178	NR	NR
Mukamal <i>et al.</i> ⁸²	2	Yang <i>et al.</i> ³⁸	Hong Kong	Stroke	Median age 57 years	Both male and female	182/3541	The Life Table method, adequate calibration	Unadjusted AUROC=0.749 (0.716 to 0.782) and adjusted AUROC=0.776
Read <i>et al.</i> ⁸³	1	Mukamal <i>et al.</i> ⁸²	USA	MI, stroke, cardiovascular death	45-84 years	Both male and female	71/843	NR	Basic model: C-statistic=0.65; basic model+CRP: C-statistic=0.66; basic model+CRP + (AB), internal carotid wall thickness, ECG left ventricular hypertrophy): C-statistic=0.68
Kiadaliri <i>et al.</i> ⁸²	1	Read <i>et al.</i> ⁸³	Scotland	Hospital admission or death from MI, stroke, unstable angina, transient ischaemic attack, peripheral vascular disease, and coronary, carotid, or major amputation procedures	30-89 years	Both male and female	14 081/181 399	Calibration plots: better calibration	C-statistic=0.674 (0.669 to 0.679)
Kiadaliri <i>et al.</i> ⁸²	1	Kiadaliri <i>et al.</i> ⁸²	Sweden	First and second events of: AMI, heart failure, non-acute IHD and stroke	Mean age 55.33 years (male) and 56.89 years (female)	Both male and female	NR/7259	HL χ^2 statistic: 11.61 (p=0.17) (first stroke); 9.99 (p=0.27) (second stroke)	C-statistic=0.79 (0.76 to 0.82) (first stroke) C-statistic=0.70 (0.64 to 0.75) (second stroke)

Continued

Table 5 Continued

Study name	No of Studies	Validation study	Location	Outcome	Age	Gender	Events (n) /total participants (N)	Calibration	Discrimination (with CI)
Davis <i>et al.</i> , (Fremantle) ³³	2	Davis <i>et al.</i> ³³	Australia	CVD (hospitalisation for/with MI or stroke, and death from cardiac or cerebrovascular causes or sudden death)	Mean age 65.3 (35.9–89.0) years	Both male and female	24/180	HL-C -test, p=0.85, good calibration	AUC=0.84 (0.76 to 0.91); p<0.001
Kengne <i>et al.</i> , (ADVANCE) ³⁴	2	Read <i>et al.</i> ⁸³	Scotland	Hospital admission or death from MI, stroke, unstable angina, transient ischaemic attack, peripheral vascular disease, and coronary, carotid or major amputation procedures	30–89 years	Both male and female	14 081/181 399	Calibration plots	C-statistic=0.665 (0.660 to 0.670)
Zethelius <i>et al.</i> ³⁵	2	Kengne <i>et al.</i> ³⁴	16 countries	CVD (fatal or non-fatal MI or stroke or cardiovascular death)	Mean age 64.4 (8.1) years	Both male and female	183/1836	HL test: p=0.032; predicted/observed risk=0.82	AUC=0.69 (0.646 to 0.724)
		Read <i>et al.</i> ⁸³	Scotland	Hospital admission or death from, stroke, unstable MI angina, transient ischaemic attack, peripheral vascular disease, and coronary, carotid, or major amputation procedures	30–89 years	Both male and female	14 081/181 399	Calibration plots	C-statistic=0.666 (0.661 to 0.671)
		Zethelius <i>et al.</i> ³⁵	Sweden	Fatal/non-fatal CVD (the composite of CHD or stroke)	30–74 years	Both male and female	522/4906	P/O ratio=0.97, modified HL χ^2 statistic=10.7 (p=0.2). Well calibration	C-statistic=0.72
Stevens <i>et al.</i> /UKPDS 66 ²⁴	1	Read <i>et al.</i> ⁸³	Scotland	Hospital admission or death from MI, stroke, unstable angina, transient ischaemic attack, peripheral vascular disease, and coronary, carotid, or major amputation procedures	30–89 years	Both male and female	14 081/181 399	Calibration plots: better calibration	C-statistic=0.663 (0.658 to 0.668)
Hippisley-Cox <i>et al.</i> /ORISK2 ³⁹	1	Yao <i>et al.</i> ⁶⁴	China	CHD, stroke	30–79 years	Both male and female	Events (n) NR/1514	NR	NR
Elley <i>et al.</i> /NZ DCS ⁴⁰	1	Read <i>et al.</i> ⁸³	Scotland	Hospital admission or death from MI, stroke, unstable angina, transient ischaemic attack, peripheral vascular disease, and coronary, carotid, or major amputation procedures	30–89 years	Both male and female	14 081/181 399	Calibration plots	C-statistic=0.674 (0.669 to 0.679)
Basu <i>et al.</i> /RECODE ³⁶	2	Read <i>et al.</i> ⁸³	Scotland	Hospital admission or death from MI, stroke, unstable angina, transient ischaemic attack, peripheral vascular disease, and coronary, carotid, or major amputation procedures	30–89 years	Both male and female	14 081/181 399	Calibration plots: better calibration	C-statistic=0.670 (0.665 to 0.674)
		Basu <i>et al.</i> ⁸⁵	USA	Nephropathy (microalbuminuria, macroalbuminuria, renal failure, ESRD, reduction in glomerular filtration rate), moderate to severe diabetic retinopathy, fatal or non-fatal MI, fatal or non-fatal stroke, CHF and all-cause mortality	45–84 years (MESA), 35–84 years (JHS)	Both male and female	89 stroke (MESA), 142 stroke (JHS)/1555 (MESA), 1746 (JHS)	Calibration slope=1.00, $\chi^2=17.3$, p value <0.001 (MESA); calibration slope=1.05, $\chi^2=22.9$, p value <0.001 (JHS)	C-statistic=0.75 for stroke (MESA); C-statistic=0.72 for stroke (JHS)

Continued

Table 5 Continued

Study name	No of Studies	Validation study	Location	Outcome	Age	Gender	Events (n) /total participants (N)	Calibration	Discrimination (with CI)
Basu <i>et al</i> ³⁶	1	Basu <i>et al</i> ³⁶	USA	Microvascular, nephropathy, retinopathy, neuropathy; cardiovascular: composite of atherosclerotic CVD (first fatal or non-fatal MI or stroke), fatal or non-fatal MI, fatal or non-fatal stroke, CHF, or death from any cardiovascular cause	Mean age of 58.9 years	Both male and female	157/4760	Calibration slope for stroke=0.99, $\chi^2=8.2$, p value=0.22	C-statistic for stroke=0.67 (0.63 to 0.71)
Alrawahi <i>et al</i> ⁴¹	1	Alrawahi <i>et al</i> ⁸⁶	Oman	Fatal and non-fatal CHD, stroke and PAD	Mean age 55.3±11.0 years (derivation sample) and 52.3±11.4 years (validation sample)	Both male and female	126 (derivation sample), 52 (validation sample) /1314 (derivation sample), 405 (validation sample)	HL χ^2 p value=0.15 (derivation sample) and HL χ^2 p value=0.06 (validation sample). Satisfactory calibration	AUC=0.73 (0.69 to 0.77) (derivation sample); AUC=0.70 (0.59 to 0.75) (validation sample).

ABI, ankle-brachial index; ADVANCE, Action in Diabetes and Vascular Disease; Preterax and Diamicon Modified Release Controlled Evaluation; AMI, acute myocardial infarction; AUC, area under the curve; AUROC, area under the receiver operating characteristic curve; CHD, coronary heart disease; CHF, congestive heart failure; CKD, chronic kidney disease; CRP, C reactive protein; CVD, cardiovascular disease; ESRD, end-stage renal disease; HL, Hosmer-Lemeshow; HL-C, Hosmer-Lemeshow C-test; IHD, ischaemic heart disease; JHS, Jackson Heart Study; MESA, Multiethnic Study of Atherosclerosis; MI, myocardial infarction; NR, not reported; NZ DCS, New Zealand Diabetes Cohort Study; PAD, peripheral artery disease; P/O, predicted over observed; RAMP-DM1, Multidisciplinary Risk Assessment and Management Program for Patients with Diabetes Mellitus; RECODe, Risk Equations for Complications of Type 2 Diabetes; ROC, receiver operating characteristic; UKPDS, United Kingdom Prospective Diabetes Study.

The overall pooled C-statistic for all validation studies was 0.68 (95% CI, 0.67 to 0.70) with high heterogeneity between studies ($I^2=95.3\%$; Cochran Q statistic $p<0.001$). Models that were developed in diabetes population showed significantly higher C-statistics than models developed in general populations (meta-regression $p=0.001$). Models, where stroke was reported as the main outcome as opposed to part of a composite CVD outcome, did show borderline significantly higher C-statistics (meta-regression $p=0.052$), although the value of the C-statistic is still low. This observed difference in the two models makes sense as models that include stroke as part of a composite outcome are expected to be different from models where stroke is the only outcome. A summary describing the characteristics of the studies where prediction models were developed in general populations but validated in patients with diabetes is presented in [table 5](#).

DISCUSSION

This systematic review and meta-analysis provides an overview of all stroke prediction models that were specifically developed for, or validated in patients with diabetes to calculate future stroke risk. Thirty-four stroke prediction models were identified that were specifically designed for patients with diabetes and only 32% of these prediction models have been externally validated, with varying results. Overall, the pooled C-statistics were poor for most models. Four of the prediction models identified were originally developed in the general population but externally validated in diabetes populations. The most notable prediction model was the UKPDS Risk Engine for Stroke²¹ with 12 validation studies. Ten stroke prediction models had multiple validations, seven models had single validations and twenty-one had no validations at all. It is difficult to assess model performance for those with no validation or single validations. Additional validation studies on the performance of stroke prediction models in different diabetes populations are needed. Since stroke prediction models developed in the general population may not account for specific risk factors related to diabetes, using risk scores developed specifically in the diabetes population will help to estimate stroke risk among people with diabetes more accurately.

None of the models showed good discriminative performance consistently when externally validated. The model by Kothari *et al*²¹ where the stroke was the primary outcome showed moderate discriminative performance (pooled C-statistic=0.72). Since this model was externally validated multiple times, the performance of this model can be considered as consistent. The discriminative ability of stroke prediction models where stroke was the primary outcome and models where stroke was a part of composite CVD outcome were modest, with C-statistics often less than 0.70.⁴² Meta-analyses of the C-statistic suggests that there is significant between-study heterogeneity in the models where stroke is reported as the primary outcome and in those where stroke is reported as part of




Figure 4 Forest plot of C-statistics, with 95% CIs, of stroke prediction models that are externally validated in two or more independent cohorts. JHS, Jackson Heart Study; MESA, Multiethnic Study of Atherosclerosis; UKPDS, United Kingdom Prospective Diabetes Study

composite CVD outcome. Further, the possible sources of heterogeneity are unexplained. Perhaps the difference in patient characteristics in the different cohorts could be a potential source of heterogeneity; however, geographic location, sample size, follow-up time, external validation and variables included in the models were not significant sources of heterogeneity in meta-regression.

The discrimination of the 17 models that were validated were generally comparable with those observed in the development cohorts. However, the performance of some models externally validated in multiple cohorts was heterogeneous and possible source for this heterogeneity remains unexplained. There was also variability in prediction model quality and the methodology used in developing them. Our study findings suggest that, from a large number of published models in patients with diabetes, very few well-validated models are available for stroke prediction. This is helpful to inform the determination of models for clinical uptake when risk stratification approaches for stroke are implemented.

No evidence of small-study effects was detected, in which smaller studies reported better discrimination of models for predicting stroke. Study quality assessment

shows many of the models failed to meet some key criteria: consideration of missing values, modelling assumptions, model validation and blinded outcome assessment, which is a concern. Many studies lacked standard reporting. This, to some extent, may be due to lack of guidelines for standards of reporting for risk prediction studies during that time. Many authors reported different aspects of prediction models, and in varying ways created difficulty in collecting information. The publication of new guidelines such as Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD)⁴³ has been introduced and may help improve reporting standards in subsequent studies in this area.

In prior reviews examining risk prediction models in adults with diabetes (Chamnan *et al*⁴⁴ van Dieren *et al*,⁴⁵ and Chowdhury *et al*¹⁶), all components of cardiovascular disease such as CHD, stroke, CAD, myocardial infarction, heart failure were considered as outcomes of the prediction model. Our review adds to knowledge on predicting risk of stroke in persons with diabetes in the following ways: (1) We only considered models where the primary outcome of the model was stroke or when stroke was part of a composite CVD outcome and corresponding

C-statistic were provided; (2) We did not consider other components of CVD as outcomes of the model and therefore our estimates of model performance are more specific to stroke; (3) We have identified and included several recently derived models and conducted meta-analyses to explore reasons for variability in the discriminative performance across models and (4) We provide a detailed assessment of quality of studies among models developed in diabetes populations. Only one prior study¹⁶ in this area performed a meta-analysis of model performance statistics across multiple studies or assessed study quality.

One of the major strengths of our study is the breadth of the systematic search, which included three different databases and extensive use of reference lists of the identified studies. Therefore, it is unlikely that any stroke prediction model-related studies have been missed. To best of our knowledge, this is the first study, where a meta-analysis and study quality assessment was performed on stroke prediction models in patients with diabetes. Nonetheless, there are few limitations in our study, which need to be kept in mind. In this paper, we only considered studies that developed or validated stroke prediction models within patients with diabetes. While prediction models for stroke have been developed for patients with other potential risk factors (eg, patients with hypertension), we felt that an exploration of a broad range of risk factors was outside the scope of this review. Though the inclusion of all stroke prediction models (regardless of the underlying risk factor(s)) could potentially improve the generalisability of our findings, it could have also increased the between-study heterogeneity, making the pooled estimates more difficult to interpret. We also did not consider non-English publications. Although, the English language is generally perceived to be the universal language of science, selection of research findings in a particular language can introduce language bias and may lead to erroneous conclusions. With this in mind, readers should be cautious when interpreting the findings of our results. Finally, we were only able to use C-statistics to compare the model performance, which might be insensitive to identify differences in the ability of models to accurately risk-stratify patients into clinically meaningful risk groups.⁴⁶ In addition, meta-analysis of calibration measures (eg, E/O ratio) along with C-statistics could give a comprehensive summary of the performance of these models.

Our findings suggest that there is no significant difference between the discrimination of models where stroke was the primary outcome and stroke was part of composite CVD outcome. Models, particularly those that have never been validated or validated once need to undergo further external validation in which they will be used with or without recalibration or model updating to better understand the comparative performance of these models.

CONCLUSIONS

In conclusion, we have identified many models for predicting stroke in patients with diabetes and attempted to compare these models. Only a small number of models have undergone external validation and might provide generalisable predictions that would support their use in another clinical setting. It is difficult to choose one model over another as none of these models exhibited superior discriminative performance, and unfortunately, no single model appears to perform consistently well. It could be argued that risk prediction in patients with diabetes is not essential. Persons with diabetes are generally perceived to be at elevated risk of stroke and the current practice is to treat to common HbA1C, blood pressure and low-density lipoprotein targets based on diabetes status alone and not on calculated risk. This non-risk based approach may be leading to unnecessary overtreatment and the absence of high-quality validated risk prediction models which limits our ability to assess whether more targeted approaches are possible. Further research is warranted to identify new risk factors with high associated relative risk to improve the currently available prediction models.

Contributors All authors contributed to this work. MZIC and TCT contributed to the conception and design of the review. MZIC and FY read and screened abstracts and titles of potentially relevant studies. MZIC and FY read the retained papers and were responsible for extracting data and rating their quality independently. MZIC performed the data analysis. MZIC drafted the paper and PER, DMR and TCT critically reviewed it and suggested amendments prior to submission. All authors approved the final version of the manuscript and take responsibility for the integrity of the reported findings.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement No data are available.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

REFERENCES

1. WHO. The top 10 causes of death. Available: <http://www.who.int/mediacentre/factsheets/fs310/en/>
2. Global Health Estimates. Geneva: World Health organization, 2012. Available: http://www.who.int/healthinfo/global_burden_disease/en/ [Accessed cited 2017 August 10].
3. Prevalence of small vessel and large vessel disease in diabetic patients from 14 centres. the world health organisation multinational study of vascular disease in diabetics. diabetes Drafting group. *Diabetologia* 1985;28(Suppl):615–40.
4. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. *Diabetes Care* 1993;16:434–44.
5. Folsom AR, Rasmussen ML, Chambless LE, et al. Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. The Atherosclerosis risk in communities (ARIC) study Investigators. *Diabetes Care* 1999;22:1077–83.
6. Lehto S, Rönnemaa T, Pyörälä K, et al. Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes. *Stroke* 1996;27:63–8.

7. Karapanayiotides T, Piechowski-Jozwiak B, van Melle G, *et al*. Stroke patterns, etiology, and prognosis in patients with diabetes mellitus. *Neurology* 2004;62:1558–62.
8. Idris I, Thomson GA, Sharma JC. Diabetes mellitus and stroke. *Int J Clin Pract* 2006;60:48–56.
9. Meads C, Ahmed I, Riley RD. A systematic review of breast cancer incidence risk prediction models with meta-analysis of their performance. *Breast Cancer Res Treat* 2012;132:365–77.
10. O'Donnell MJ, Xavier D, Liu L, *et al*. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. *The Lancet* 2010;376:112–23.
11. Sacco RL, Benjamin EJ, Broderick JP, *et al*. Risk factors. *Stroke* 1997;28:1507–17.
12. Boehme AK, Esenwa C, Elkind MSV, *et al*. Stroke risk factors, genetics, and prevention. *Circ Res* 2017;120:472–95.
13. Tuttolomondo A, Pecoraro R, Simonetta I, *et al*. Neurological complications of Anderson-Fabry disease. *Curr Pharm Des* 2013;19:6014–30.
14. Tuttolomondo A, Pecoraro R, Simonetta I, *et al*. Anderson-Fabry disease: a multiorgan disease. *Curr Pharm Des* 2013;19:5974–96.
15. Brownrigg JRW, de Lusignan S, McGovern A, *et al*. Peripheral neuropathy and the risk of cardiovascular events in type 2 diabetes mellitus. *Heart* 2014;100:1837–43.
16. Chowdhury MZI, Yeasmin F, Rabi DM, *et al*. Prognostic tools for cardiovascular disease in patients with type 2 diabetes: a systematic review and meta-analysis of C-statistics. *J Diabetes Complications* 2019;33:98–111.
17. Moons KGM, de Groot JAH, Bouwmeester W, *et al*. Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the charms checklist. *PLoS Med* 2014;11:e1001744.
18. Moher D, Liberati A, Tetzlaff J, *et al*. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;6:e1000097.
19. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. *Radiology* 1982;143:29–36.
20. Egger M, Davey-Smith G, Altman D, eds. *Systematic reviews in health care: meta-analysis in context*. John Wiley & Sons, 2008.
21. Kothari V, Stevens RJ, Adler AI, *et al*. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK prospective diabetes study risk engine. *Stroke* 2002;33:1776–81.
22. Ahmad Kiadaliri A, Gerdttham U-G, Nilsson P, *et al*. Towards renewed health economic simulation of type 2 diabetes: risk equations for first and second cardiovascular events from Swedish register data. *PLoS One* 2013;8:e62650.
23. Palmer CNA, Kimber CH, Doney ASF, *et al*. Combined effect of inflammatory gene polymorphisms and the risk of ischemic stroke in a prospective cohort of subjects with type 2 diabetes: a Go-DARTS study. *Diabetes* 2010;59:2945–8.
24. Stevens RJ, Coleman RL, Adler AI, *et al*. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. *Diabetes Care* 2004;27:201–7.
25. Ofstad AP, Gullestad L, Orvik E, *et al*. Interleukin-6 and activin A are independently associated with cardiovascular events and mortality in type 2 diabetes: the prospective Asker and Bærum cardiovascular diabetes (ABCD) cohort study. *Cardiovasc Diabetol* 2013;12:126.
26. Stevens RJ, Kothari V, Adler AI, *et al*. The UKPDS Risk Engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). *Clin Sci* 2001;101:671–9.
27. Clarke PM, Gray AM, Briggs A, *et al*. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) outcomes model (UKPDS No. 68). *Diabetologia* 2004;47:1747–59.
28. Anderson KM, Odell PM, Wilson PW, *et al*. Cardiovascular disease risk profiles. *Am Heart J* 1991;121:293–8.
29. D'Agostino RB, Vasan RS, Pencina MJ, *et al*. General cardiovascular risk profile for use in primary care: the Framingham heart study. *Circulation* 2008;117:743e53.
30. Ataoglu HE, Saler T, Uzunhasan I, *et al*. Improvement of cardiovascular risk assessment in type 2 diabetes by the addition of carotid artery intima-media thickness to Framingham risk score: a retrospective cohort study. *J Diabetes* 2009;1:188–93.
31. Kengne AP, Patel A, Colagiuri S, *et al*. The Framingham and UK prospective diabetes study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the action in diabetes and vascular disease: Preterax and Diamicon-MR controlled evaluation (advance) study. *Diabetologia* 2010;53:821–31.
32. Mukamal KJ, Kizer JR, Djoussé L, *et al*. Prediction and classification of cardiovascular disease risk in older adults with diabetes. *Diabetologia* 2013;56:275–83.
33. Davis WA, Knuiman MW, Davis TME. An Australian cardiovascular risk equation for type 2 diabetes: the Fremantle diabetes study. *Intern Med J* 2010;40:286–92.
34. Kengne AP, Patel A, Marre M, *et al*. Contemporary model for cardiovascular risk prediction in people with type 2 diabetes. *Eur J Cardiovasc Prev Rehabil* 2011;18:393–8.
35. Zethelius B, Eliasson B, Eeg-Olofsson K, *et al*. A new model for 5-year risk of cardiovascular disease in type 2 diabetes, from the Swedish national diabetes register (NDR). *Diabetes Res Clin Pract* 2011;93:276–84.
36. Basu S, Sussman JB, Berkowitz SA, *et al*. Development and validation of risk equations for complications of type 2 diabetes (RECODE) using individual participant data from randomised trials. *Lancet Diabetes Endocrinol* 2017;5:788–98.
37. D'Agostino RB, Wolf PA, Belanger AJ, *et al*. Stroke risk profile: adjustment for antihypertensive medication. The Framingham study. *Stroke* 1994;25:40–3.
38. Yang X, So W-Y, Kong APS, *et al*. Development and validation of stroke risk equation for Hong Kong Chinese patients with type 2 diabetes: the Hong Kong diabetes registry. *Diabetes Care* 2007;30:65–70.
39. Hippisley-Cox J, Coupland C, Vinogradova Y, *et al*. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. *BMJ* 2008;336:1475–82.
40. Elley CR, Robinson E, Kenealy T, *et al*. Derivation and validation of a new cardiovascular risk score for people with type 2 diabetes: the New Zealand diabetes cohort study. *Diabetes Care* 2010;33:1347–52.
41. Alrawahi AH, Lee P, Al-Anquodi ZAM, *et al*. Cardiovascular risk prediction model for Omanis with type 2 diabetes. *Diabetes Metab Syndr* 2018;12:105–10.
42. Hosmer DW, Lemeshow S. *Applied logistic regression*. 2nd Edition. New York, NY: John Wiley & Sons, 2000.
43. Collins GS, Reitsma JB, Altman DG, *et al*. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. *Ann Intern Med* 2015;162:55–63.
44. Chamnan P, Simmons RK, Sharp SJ, *et al*. Cardiovascular risk assessment scores for people with diabetes: a systematic review. *Diabetologia* 2009;52:e14:2001–14.
45. van Dieren S, Beulens JWW, Kengne AP, *et al*. Prediction models for the risk of cardiovascular disease in patients with type 2 diabetes: a systematic review. *Heart* 2012;98:360–9.
46. Cook NR, Ridker PM. Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. *Ann Intern Med* 2009;150:795–802.
47. Wells BJ, Roth R, Nowacki AS, *et al*. Prediction of morbidity and mortality in patients with type 2 diabetes. *PeerJ* 2013;1:e87.
48. Tanaka S, Tanaka S, Iimuro S, *et al*. Predicting macro- and microvascular complications in type 2 diabetes: the Japan diabetes complications Study/the Japanese elderly diabetes intervention trial risk engine. *Diabetes Care* 2013;36:1193–9.
49. Li T-C, Wang H-C, Li C-I, *et al*. Establishment and validation of a prediction model for ischemic stroke risks in patients with type 2 diabetes. *Diabetes Res Clin Pract* 2018;138:220–8.
50. Khalili S, Hatami M, Hadaegh F, *et al*. Prediction of cardiovascular events with consideration of general and central obesity measures in diabetic adults: results of the 8.4-year follow-up. *Metab Syndr Relat Disord* 2012;10:218–224.
51. Cederholm J, Eeg-Olofsson K, Eliasson B, *et al*. Risk prediction of cardiovascular disease in type 2 diabetes: a risk equation from the Swedish national diabetes register. *Diabetes Care* 2008;31:2038–43.
52. Looker HC, Colombo M, Agakov F, *et al*. Protein biomarkers for the prediction of cardiovascular disease in type 2 diabetes. *Diabetologia* 2015;58:1363–71.
53. Paynter NP, Mazer NA, Pradhan AD, *et al*. Cardiovascular risk prediction in diabetic men and women using hemoglobin A1c vs diabetes as a high-risk equivalent. *Arch Intern Med* 2011;171:1712–8.
54. Price AH, Welsh P, Weir CJ, *et al*. N-Terminal pro-brain natriuretic peptide and risk of cardiovascular events in older patients with type 2 diabetes: the Edinburgh type 2 diabetes study. *Diabetologia* 2014;57:2505–12.
55. Selby JV, Karter AJ, Ackerson LM, *et al*. Developing a prediction rule from automated clinical databases to identify high-risk patients in a large population with diabetes. *Diabetes Care* 2001;24:1547–55.
56. Zarkogianni K, Athanasiou M, Thanopoulou AC, *et al*. Comparison of machine learning approaches toward assessing the risk of developing cardiovascular disease as a long-term diabetes complication. *IEEE J Biomed Health Inform* 2018;22:1637–47.
57. Price AH, Weir CJ, Welsh P, *et al*. Comparison of non-traditional biomarkers, and combinations of biomarkers, for vascular risk

- prediction in people with type 2 diabetes: the Edinburgh type 2 diabetes study. *Atherosclerosis* 2017;264:67–73.
58. Wan EYF, Fong DYT, Fung CSC, *et al.* Development of a cardiovascular diseases risk prediction model and tools for Chinese patients with type 2 diabetes mellitus: a population-based retrospective cohort study. *Diabetes Obes Metab* 2018;20:309–18.
 59. Young JB, Gauthier-Loiselle M, Bailey RA, *et al.* Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data. *Cardiovasc Diabetol* 2018;17:118.
 60. van der Leeuw J, Beulens JWW, van Dieren S, *et al.* Novel biomarkers to improve the prediction of cardiovascular event risk in type 2 diabetes mellitus. *J Am Heart Assoc* 2016;5:e003048.
 61. Alshehry ZH, Mundra PA, Barlow CK, *et al.* Plasma lipidomic profiles improve on traditional risk factors for the prediction of cardiovascular events in type 2 diabetes mellitus. *Circulation* 2016;134:1637–50.
 62. Woodward M, Hirakawa Y, Kengne A-P, *et al.* Prediction of 10-year vascular risk in patients with diabetes: the AD-ON risk score. *Diabetes Obes Metab* 2016;18:289–94.
 63. Parrinello CM, Matsushita K, Woodward M, *et al.* Risk prediction of major complications in individuals with diabetes: the Atherosclerosis risk in Communities study. *Diabetes Obes Metab* 2016;18:899–906.
 64. Colombo M, Looker HC, Farran B, *et al.* Apolipoprotein CIII and N-terminal prohormone B-type natriuretic peptide as independent predictors for cardiovascular disease in type 2 diabetes. *Atherosclerosis* 2018;274:182–90.
 65. Davis WA, Colagiuri S, Davis TME. Comparison of the Framingham and United Kingdom Prospective Diabetes Study cardiovascular risk equations in Australian patients with type 2 diabetes from the Fremantle Diabetes Study. *Med J Aust* 2009;190:180–4.
 66. Jiao FF, Fung CSC, Wong CKH, *et al.* Effects of the multidisciplinary risk assessment and management program for patients with diabetes mellitus (RAMP-DM) on biomedical outcomes, observed cardiovascular events and cardiovascular risks in primary care: a longitudinal comparative study. *Cardiovasc Diabetol* 2014;13:127.
 67. Lahoz-Rallo B, Blanco-Gonzalez M, Casas-Ciria I, *et al.* Cardiovascular disease risk in subjects with type 2 diabetes mellitus in a population in southern Spain. *Diabetes Res Clin Pract* 2007;76:436–44.
 68. Metcalf PA, Wells S, Scragg RKR, *et al.* Comparison of three different methods of assessing cardiovascular disease risk in new Zealanders with type 2 diabetes mellitus. *N Z Med J* 2008;121:49–57.
 69. Bannister CA, Poole CD, Jenkins-Jones S, *et al.* External validation of the UKPDS risk engine in incident type 2 diabetes: a need for new type 2 diabetes-specific risk equations. *Diabetes Care* 2014;37:537–45.
 70. Wu Y, He J, Sun X, *et al.* Carotid atherosclerosis and its relationship to coronary heart disease and stroke risk in patients with type 2 diabetes mellitus. *Medicine* 2017;96:e8151.
 71. Ipadeola A, Adeleye JO. The metabolic syndrome and accurate cardiovascular risk prediction in persons with type 2 diabetes mellitus. *Diabetes Metab Syndr* 2016;10:7–12.
 72. Leal J, Hayes AJ, Gray AM, *et al.* Temporal validation of the UKPDS outcomes model using 10-year posttrial monitoring data. *Diabetes Care* 2013;36:1541–6.
 73. McEwan P, Bennett H, Ward T, *et al.* Refitting of the UKPDS 68 risk equations to contemporary routine clinical practice data in the UK. *Pharmacoeconomics* 2015;33:149–61.
 74. Pagano E, Gray A, Rosato R, *et al.* Prediction of mortality and macrovascular complications in type 2 diabetes: validation of the UKPDS outcomes model in the Casale Monferrato survey, Italy. *Diabetologia* 2013;56:1726–34.
 75. Tao L, Wilson ECF, Griffin SJ, *et al.* Performance of the UKPDS outcomes model for prediction of myocardial infarction and stroke in the ADDITION-Europe trial cohort. *Value Health* 2013;16:1074–80.
 76. Shivakumar V, Kandhare AD, Rajmane AR, *et al.* Estimation of the long-term cardiovascular events using UKPDS risk engine in metabolic syndrome patients. *Indian J Pharm Sci* 2014;76:174.
 77. Moazzam A, Amer J, Rehan N. Estimating the risk of cardiovascular diseases among Pakistani diabetics using UKPDS risk engine. *Journal of Ayub Medical College Abbottabad* 2015;27:277–9.
 78. Ezenwaka CE, Nwagbara E, Seales D, *et al.* Prediction of 10-year coronary heart disease risk in Caribbean type 2 diabetic patients using the UKPDS risk engine. *Int J Cardiol* 2009;132:348–53.
 79. Sun X, He J, Ji X-L, *et al.* Association of chronic kidney disease with coronary heart disease and stroke risks in patients with type 2 diabetes mellitus: an observational cross-sectional study in Hangzhou, China. *Chin Med J* 2017;130:57–63.
 80. Pang X-H, Han J, Ye W-L, *et al.* Lower extremity peripheral arterial disease is an independent predictor of coronary heart disease and stroke risks in patients with type 2 diabetes mellitus in China. *Int J Endocrinol* 2017;2017:9620513–6.
 81. Herder C, Schöttker B, Rothenbacher D, *et al.* Interleukin-6 in the prediction of primary cardiovascular events in diabetes patients: results from the ESTHER study. *Atherosclerosis* 2011;216:244–7.
 82. Costa B, Cabré JJ, Martín F, *et al.* [The Framingham function overestimates stroke risk for diabetes and metabolic syndrome among Spanish population]. *Aten Primaria* 2005;35:392–8.
 83. Read SH, van Diepen M, Colhoun HM, *et al.* Performance of cardiovascular disease risk scores in people diagnosed with type 2 diabetes: external validation using data from the National Scottish diabetes register. *Diabetes Care* 2018;41:2010–8.
 84. Yao M-F, He J, Sun X, *et al.* Gender differences in risks of coronary heart disease and stroke in patients with type 2 diabetes mellitus and their association with metabolic syndrome in China. *Int J Endocrinol* 2016;2016:8483405–7.
 85. Basu S, Sussman JB, Berkowitz SA, *et al.* Validation of risk equations for complications of type 2 diabetes (RECODE) using individual participant data from diverse longitudinal cohorts in the U.S. *Diabetes Care* 2018;41:586–95.
 86. Alrawahi AH, Lee P. Validation of the cardiovascular risk model developed for Omanis with type 2 diabetes. *Diabetes Metab Syndr* 2018;12:387–91.